Left ventricular assist device and transcatheter edge-to-edge mitral valve repair in advanced heart failure: allies or enemies?
暂无分享,去创建一个
F. Righini | C. Sciaccaluga | S. Bernazzali | S. Valente | M. Gitto | M. Maccherini | Francesco Gentile | Italy Massimo Mapelli Monzino Cardiology Center | C. S. Dini | M. Cameli | V. Tarzia | G. Gerosa
[1] A. Lorts,et al. Durable Mechanical Circulatory Support: JACC Scientific Statement. , 2023, Journal of the American College of Cardiology.
[2] G. Stone,et al. Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation. , 2023, The New England journal of medicine.
[3] W. Rottbauer,et al. Contemporary Outcomes Following Transcatheter Edge-to-Edge Repair: 1-Year Results From the EXPAND Study. , 2023, JACC. Cardiovascular interventions.
[4] J. Zamorano,et al. Safety and efficacy of MitraClip in acutely ill (NYHA Class IV) patients with mitral regurgitation: Results from the global EXPAND study , 2023, ESC heart failure.
[5] N. Uriel,et al. Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial. , 2022, JAMA.
[6] M. Metra,et al. Prognostic impact of the updated 2018 HFA‐ESC definition of advanced heart failure: results from the HELP‐HF registry , 2022, European journal of heart failure.
[7] L. Lund,et al. Improved survival of left ventricular assist device carriers in Europe according to implantation eras: results from the PCHF‐VAD registry , 2022, European journal of heart failure.
[8] M. Link,et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Journal of the American College of Cardiology.
[9] G. Sinagra,et al. [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.
[10] Elias Mossialos,et al. A clinical and cost-effectiveness analysis of the HeartMate 3 left ventricular assist device for transplant-ineligible patients: A United Kingdom perspective. , 2021, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[11] M. Morshuis,et al. Safety, Mortality, and Hemodynamic Impact of Patients with MitraClip Undergoing Left Ventricular Assist Device Implantation , 2021, Journal of Cardiovascular Translational Research.
[12] Natasha Meunier-McVey,et al. 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure , 2021, EMJ Cardiology.
[13] S. Russell,et al. Guidance for Timely and Appropriate Referral of Patients With Advanced Heart Failure: A Scientific Statement From the American Heart Association , 2021, Circulation.
[14] B. Prendergast,et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. , 2021, European heart journal.
[15] J. Cleveland,et al. Primary results of long‐term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implants , 2021, European Journal of Heart Failure.
[16] L. Lund,et al. The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019 , 2021, European journal of heart failure.
[17] J. Cleveland,et al. Clinical outcomes and healthcare expenditures in the real world with left ventricular assist devices - The CLEAR-LVAD study. , 2021, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[18] M. Mack,et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Circulation.
[19] H. Katus,et al. MitraClip implantation followed by insertion of a left ventricular assist device in patients with advanced heart failure , 2020, ESC heart failure.
[20] M. Morshuis,et al. Two-year outcome after implantation of a full magnetically levitated left ventricular assist device: results from the ELEVATE Registry. , 2020, European heart journal.
[21] M. Metra,et al. MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry. , 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[22] J. Rogers,et al. Advanced Heart Failure: Epidemiology, Diagnosis, and Therapeutic Approaches. , 2020, JACC. Heart failure.
[23] J. Cleveland,et al. Impact of left ventricular assist device implantation on mitral regurgitation: An analysis from the MOMENTUM 3 trial. , 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[24] M. Mack,et al. Cost-Effectiveness of Transcatheter Mitral Valve Repair versus Medical Therapy in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial. , 2019, Circulation.
[25] M. Frigerio,et al. Safety of centrifugal left ventricular assist device in patients previously treated with MitraClip system. , 2019, International journal of cardiology.
[26] M. Walsh,et al. A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report , 2019, The New England journal of medicine.
[27] A. Sannino,et al. Proportionate and Disproportionate Functional Mitral Regurgitation: A New Conceptual Framework That Reconciles the Results of the MITRA-FR and COAPT Trials. , 2019, JACC. Cardiovascular imaging.
[28] M. Mack,et al. Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial , 2018, American heart journal.
[29] M. Mack,et al. Transcatheter Mitral‐Valve Repair in Patients with Heart Failure , 2018, The New England journal of medicine.
[30] D. Maucort-Boulch,et al. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation , 2018, The New England journal of medicine.
[31] G. Filippatos,et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology , 2018, European journal of heart failure.
[32] A. Haverich,et al. MitraClip procedure prior to left ventricular assist device implantation. , 2018, Journal of thoracic disease.
[33] M. Metra,et al. Heart failure , 2017, The Lancet.
[34] J. Baumwol. "I Need Help"-A mnemonic to aid timely referral in advanced heart failure. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[35] Danielle M. Enserro,et al. Prevalence, Neurohormonal Correlates, and Prognosis of Heart Failure Stages in the Community. , 2016, JACC. Heart failure.
[36] J. Butler,et al. Defining Advanced Heart Failure: A Systematic Review of Criteria Used in Clinical Trials. , 2016, Journal of cardiac failure.
[37] J. Cleveland,et al. Clinical trial design and rationale of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) investigational device exemption clinical study protocol. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[38] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.
[39] J. Caro. ESC/EACTS Guidelines on the management of valvular heart disease , 2012 .